Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Yonghong Yan was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Dec 31
Guangdong Guanghua Sci-Tech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 공시 • Sep 30
Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q3, 2025 Results on Oct 27, 2025 Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q3, 2025 results on Oct 27, 2025 공시 • Sep 04
Guangdong Guanghua Sci-Tech Co., Ltd. Approves Board Elections Guangdong Guanghua Sci-Tech Co., Ltd. its 1st Extraordinary General Meeting of 2025 on 02 September 2025 approved the election of Yan Yonghong, independent director and Xu Tao, independent director. 공시 • Jul 02
Guangdong Guanghua Sci-Tech Co., Ltd. to Report First Half, 2025 Results on Aug 30, 2025 Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report first half, 2025 results on Aug 30, 2025 공시 • Apr 24
Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 15, 2025 Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 15, 2025, at 14:30 China Standard Time. Location: 5F, No. 295, Daxue Road, Shantou, Guangdong China 공시 • Mar 31
Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 공시 • Dec 31
Guangdong Guanghua Sci-Tech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 New Risk • Nov 16
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (0.8% operating cash flow to total debt). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). Board Change • Nov 12
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhen Feng Liang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.01 loss per share (vs CN¥0.27 loss in 3Q 2023) Third quarter 2024 results: CN¥0.01 loss per share (improved from CN¥0.27 loss in 3Q 2023). Revenue: CN¥663.0m (down 7.5% from 3Q 2023). Net loss: CN¥3.96m (loss narrowed 96% from 3Q 2023). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. 공시 • Sep 30
Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 26
Second quarter 2024 earnings released: EPS: CN¥0.017 (vs CN¥0.069 loss in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.017 (up from CN¥0.069 loss in 2Q 2023). Revenue: CN¥658.5m (up 7.8% from 2Q 2023). Net income: CN¥6.94m (up CN¥34.5m from 2Q 2023). Profit margin: 1.1% (up from net loss in 2Q 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. New Risk • Jul 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change). 공시 • Jun 29
Guangdong Guanghua Sci-Tech Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024 New Risk • May 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). 공시 • Apr 29
Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 17, 2024 Guangdong Guanghua Sci-Tech Co., Ltd., Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Shantou, Guangdong China 공시 • Dec 30
Guangdong Guanghua Sci-Tech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.062 profit in 3Q 2022) Third quarter 2023 results: CN¥0.16 loss per share (down from CN¥0.062 profit in 3Q 2022). Revenue: CN¥733.1m (down 20% from 3Q 2022). Net loss: CN¥63.7m (down 361% from profit in 3Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. 공시 • Sep 30
Guangdong Guanghua Sci-Tech Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023 Guangdong Guanghua Sci-Tech Co., Ltd. announced that they will report Q3, 2023 results on Oct 31, 2023 Board Change • Sep 22
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhen Feng Liang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 31
Second quarter 2023 earnings released: CN¥0.069 loss per share (vs CN¥0.12 profit in 2Q 2022) Second quarter 2023 results: CN¥0.069 loss per share (down from CN¥0.12 profit in 2Q 2022). Revenue: CN¥610.9m (down 39% from 2Q 2022). Net loss: CN¥27.6m (down 158% from profit in 2Q 2022). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Reported Earnings • Mar 08
Full year 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.16 in FY 2021) Full year 2022 results: EPS: CN¥0.30 (up from CN¥0.16 in FY 2021). Revenue: CN¥3.30b (up 28% from FY 2021). Net income: CN¥116.9m (up 88% from FY 2021). Profit margin: 3.5% (up from 2.4% in FY 2021). Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Zhen Feng Liang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.062 (vs CN¥0.051 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.062 (up from CN¥0.051 in 3Q 2021). Revenue: CN¥914.5m (up 34% from 3Q 2021). Net income: CN¥24.4m (up 29% from 3Q 2021). Profit margin: 2.7% (down from 2.8% in 3Q 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Board Change • Oct 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Zhen Feng Liang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 27
Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.049 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.12 (up from CN¥0.049 in 2Q 2021). Revenue: CN¥1.01b (up 58% from 2Q 2021). Net income: CN¥47.2m (up 142% from 2Q 2021). Profit margin: 4.7% (up from 3.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Yuping Wu was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 01
Second quarter 2021 earnings released: EPS CN¥0.049 (vs CN¥0.064 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥635.8m (up 3.9% from 2Q 2020). Net income: CN¥19.5m (down 20% from 2Q 2020). Profit margin: 3.1% (down from 4.0% in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 17
Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.04 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.01b (up 18% from FY 2019). Net income: CN¥36.6m (up 171% from FY 2019). Profit margin: 1.8% (up from 0.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Feb 27
New 90-day high: CN¥13.98 The company is up 6.0% from its price of CN¥13.19 on 27 November 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period. Is New 90 Day High Low • Dec 16
New 90-day low: CN¥12.32 The company is down 17% from its price of CN¥14.81 on 18 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Nov 27
New 90-day low: CN¥12.97 The company is down 6.0% from its price of CN¥13.75 on 28 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Oct 30
New 90-day low: CN¥13.21 The company is down 3.0% from its price of CN¥13.55 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. Reported Earnings • Oct 26
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥706.8k, down 98% from the prior year. Total revenue was CN¥1.87b over the last 12 months, up 19% from the prior year. Is New 90 Day High Low • Oct 12
New 90-day high: CN¥15.26 The company is up 17% from its price of CN¥13.04 on 14 July 2020. The Chinese market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 2.0% over the same period.